Medicine guide

Zalmoxis

Active substance: Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)
Used in: Cancer treatments and immune-system medicines
Made by: MolMed SpA
Source: Official label

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Zalmoxis is indicated as adjunctive treatment in haploidentical haematopoietic stem cell transplantation (HSCT) of adult patients with high-risk haematological malignancies.

From the official label · 2026-09-30 · European Medicines Agency

Made by	MolMed SpA
Active substance	Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)
Used in	Cancer treatments and immune-system medicines
Classification	L01 · Cancer treatments and immune-system medicines
Authorised on	2016-08-18
Last updated by the regulator	2020-02-14
EMA product number	EMEA/H/C/002801

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).